CLINICAL IMPORTANCE OF D-1 AND D-2 RECEPTORS

[1] PRELIMINARY OBSERVATIONS ON ABNORMAL CATECHOLAMINE METABOLISM IN BASAL GANGLIA DISEASES [J]. NEUROLOGY, 1960, 10 (05) : 446 - 451

[2] CHRONIC TREATMENT WITH L-DOPA, BUT NOT BROMOCRIPTINE INDUCES DYSKINESIA IN MPTP-PARKINSONIAN MONKEYS - CORRELATION WITH [H-3] SPIPERONE BINDING [J]. BRAIN RESEARCH, 1986, 379 (02) : 294 - 299

[3] BIRKMAYER W, 1961, Wien Klin Wochenschr, V73, P787

[4] [H-3] SPIPERONE BINDING, DOPAMINE AND HVA CONCENTRATIONS IN PARKINSONS-DISEASE AND SUPRANUCLEAR PALSY [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 99 (2-3) : 167 - 175

[5] STIMULATION OF BOTH D1 AND D2 DOPAMINE-RECEPTORS APPEARS NECESSARY FOR FULL EXPRESSION OF POSTSYNAPTIC EFFECTS OF DOPAMINE AGONISTS - A NEUROPHYSIOLOGICAL STUDY [J]. BRAIN RESEARCH, 1987, 400 (02) : 205 - 218

[6] D-2 DOPAMINE RECEPTOR-MEDIATED INHIBITION OF ADENYLATE-CYCLASE ACTIVITY IN THE INTERMEDIATE LOBE OF THE RAT PITUITARY-GLAND REQUIRES GUANOSINE 5'-TRIPHOSPHATE [J]. ENDOCRINOLOGY, 1982, 110 (03) : 812 - 819

[7] NIGROSTRIATAL LESIONS ENHANCE STRIATAL APOMORPHINE-H-3 AND H-3-SPIROPERIDOL BINDING [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1979, 56 (03) : 277 - 281

[8] FARLEY IJ, 1976, ADV PARKINSONISM, P178

[9] Fuxe K, 1985, BASIC CLIN ASPECTS N, P11

[10] A POSSIBLE MOLECULAR MECHANISM FOR THE ANTIPARKINSONIAN ACTION OF BROMOCRIPTINE IN COMBINATION WITH LEVODOPA [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1985, 6 (11) : 436 - 437

[1] PRELIMINARY OBSERVATIONS ON ABNORMAL CATECHOLAMINE METABOLISM IN BASAL GANGLIA DISEASES [J]. NEUROLOGY, 1960, 10 (05) : 446 - 451

[2] CHRONIC TREATMENT WITH L-DOPA, BUT NOT BROMOCRIPTINE INDUCES DYSKINESIA IN MPTP-PARKINSONIAN MONKEYS - CORRELATION WITH [H-3] SPIPERONE BINDING [J]. BRAIN RESEARCH, 1986, 379 (02) : 294 - 299

[3] BIRKMAYER W, 1961, Wien Klin Wochenschr, V73, P787

[4] [H-3] SPIPERONE BINDING, DOPAMINE AND HVA CONCENTRATIONS IN PARKINSONS-DISEASE AND SUPRANUCLEAR PALSY [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 99 (2-3) : 167 - 175

[5] STIMULATION OF BOTH D1 AND D2 DOPAMINE-RECEPTORS APPEARS NECESSARY FOR FULL EXPRESSION OF POSTSYNAPTIC EFFECTS OF DOPAMINE AGONISTS - A NEUROPHYSIOLOGICAL STUDY [J]. BRAIN RESEARCH, 1987, 400 (02) : 205 - 218

[6] D-2 DOPAMINE RECEPTOR-MEDIATED INHIBITION OF ADENYLATE-CYCLASE ACTIVITY IN THE INTERMEDIATE LOBE OF THE RAT PITUITARY-GLAND REQUIRES GUANOSINE 5'-TRIPHOSPHATE [J]. ENDOCRINOLOGY, 1982, 110 (03) : 812 - 819

[7] NIGROSTRIATAL LESIONS ENHANCE STRIATAL APOMORPHINE-H-3 AND H-3-SPIROPERIDOL BINDING [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1979, 56 (03) : 277 - 281

[8] FARLEY IJ, 1976, ADV PARKINSONISM, P178

[9] Fuxe K, 1985, BASIC CLIN ASPECTS N, P11

[10] A POSSIBLE MOLECULAR MECHANISM FOR THE ANTIPARKINSONIAN ACTION OF BROMOCRIPTINE IN COMBINATION WITH LEVODOPA [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1985, 6 (11) : 436 - 437